SKYE BIOSCIENCE INC

SKYENASDAQ

🏆 #3605 by market capEarnings Aug 13US Equity

$0.54▲ $0.00 (+0.39%)

🌙 After hours$0.55▲ 1.68%Regular close · extended-hours price shown

1h—

24h▲ 0.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$19M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

No chart data available for SKYE.

Trading Snapshot

Day Range: $0.53 – $0.55
52-Week Range: $0.28 – $4.99
Volume: $2.02B
Avg Volume: $2.55B
Shares Outstanding: 35.1M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $776,233
P/E Ratio: -0.4
P/S Ratio: 0.0x
EPS (TTM): $-1.44
Dividend Yield: 0.00%

Why Investors Own SKYE

✓High-growth profile — revenue up +1.2% YoY with expanding US Equity exposure.
✓Healthy economics — 61% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$3M▲ +6.0% YoY

Gross Margin (TTM)

60.7%▲ +1.2% YoY

Operating Income (TTM)

$1M▲ +6.0% YoY

Free Cash Flow (TTM)

$161,095▲ +6.0% YoY

About SKYE BIOSCIENCE INC

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

🦦